DC Appeals Court Sides With FDA In Mylan's Patent Challenge For Duragesic
A federal judge has ruled that the U.S. Food and Drug Administration (FDA) acted appropriately in withdrawing its final approval of Mylan Laboratories's Abbreviated New Drug Application (ANDA) for its generic...To view the full article, register now.
Already a subscriber? Click here to view full article